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Abstract The goal of this randomized, blinded, crossover
clinical trial was to determine whether Nuedexta (dextrome-
thorphan and quinidine) enhanced speech, swallowing, and
salivation in patients with ALS. Sixty patients with amyotro-
phic lateral sclerosis (ALS) received either Nuedexta or pla-
cebo for 28 to 30 days, followed by a 10 to 15-day washout
period. Subsequently, patients were switched to the opposite
treatment arm for the remaining days of the trial. The primary
endpoint was a reduction in the self-report Center for
Neurologic Study Bulbar Function Scale (CNS-BFS) score.
The rater-administered ALS Functional Rating Scale Revised
was the principal secondary endpoint. The CNS-BFS score
improved with active treatment, decreasing from a mean of
59.3 in the placebo arm of the trial to 53.5 during the drug-
treatment arm (p < 0.001). Each of the individual domains of
bulbar function interrogated by the CNS-BFS responded to
treatment with Nuedexta as follows: salivation: 15.8 versus
14.3 (p = 0.004); speech: 24.6 versus 22.2 (p = 0.003);
swallowing: 18.9 versus 17.1 (p = 0.009). Similarly, the bulbar
component of the ALS Functional Rating Scale Revised im-
proved with active treatment (p = 0.003), although the drug
did not affect the motor and respiratory components of this
scale. This study is unique for several reasons. Firstly, it was
driven by patient reports of improved speech and swallowing
while taking Nuedexta for control of emotional lability.
Secondly, the study was conducted over a short duration
(70 days), and thirdly, a self-report scale was selected as the
principle outcome measure. Considering the importance of bul-
bar functions, these results, if confirmed, point to an additional
use of Nuedexta as an adjunct to the management of ALS.
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Introduction
To date, palliative care has been the mainstay of treatment for
bulbar symptoms that account for much of the disability that
accompanies motor neuron disease [1–4]. For example, percuta-
neous gastrostomy is recommended for patients who are unable
to maintain their weight or swallow effectively. On this back-
ground, it was unexpected when patients treated with Nuedexta
(DMQ), approved in 2011 for the treatment of labile emotionality
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(pseudobulbar affect) that occurs in associationwith amyotrophic
lateral sclerosis (ALS) [5, 6], reported improvements in speech,
swallowing, and the ability to handle oral secretions.
DMQ contains both dextromethorphan (DM) and quin-
idine. The latter protects DM from O-demethylation by
inhibiting the cytochrome P450 isoenzyme CYP2D6 [7].
As is true for many other psychoactive drugs, DM ex-
hibits molecular promiscuity [8]. First recognized as a
weak uncompetitive antagonist of N-methyl-D-aspartate
receptors [9], DM was subsequently discovered to be a
sigma-1 receptor agonist [10]. These inhibit voltage
gated-ion channels, potentiate ligand-gated channels
[11], and exert a modest effect on serotonin uptake [12].
These properties have suggested the drug may be useful
for a variety of clinical applications [13, 14].
To us, the clue suggesting that a drug that palliates
pseudobulbar affect (PBA) might enhance bulbar function
was provided by Parvizi et al. [15], who postulated that the
brainstem and cerebellum are involved in the regulation of
emotional expression. As sigma-1 receptors are preferentially
localized to these structures [16], and recently found to deco-
rate brainstem motor neurons, we felt it reasonable to expect
that DMQ, a sigma-1 agonist, might also palliate speech and
swallowing, as well as PBA.
For the most part, ALS drug trials have focused on survival
as an endpoint. These studies typically utilize a parallel design
and have extended for long intervals, often up to 18 months.
With one exception [17], these have failed, whereas studies
that focused on symptomatic treatment, such as the use of bi-
level positive airway pressure for treatment of respiratory fail-
ure, have demonstrated a survival benefit associated with an
enhanced quality of life [18]. Accordingly, we thought it im-
portant to confirm the palliative effect of DMQ on bulbar
symptoms as reported by patients, family members, and
physicians.
As the clinical assessment of bulbar function has not yet
attained the standard of practice that is universally employed
for the assessment of limb musculature and respiratory func-
tion, we set out to develop a self-report bulbar function scale,
the Center for Neurologic Study Bulbar Function Scale (CNS-
BFS). This was modeled after the Center for Neurologic Study
Emotional Lability Scale (CNS-LS) that has proven to be a
robust endpoint in 4 clinical trials [5, 19–21]. The CNS-BFS
interrogates 3 domains of bulbar function: speech,
swallowing, and salivation (see Table 1). For each domain,
patients are asked to rate 7 statements or questions on a scale
of 1 to 5. Patients unable to speak are assigned a value of 6 for
the speech domain questions. This allows for a global score
ranging from 21 to 112. The principal goal of this study was to
determine whether DMQ exerts a palliative effect on speech,
swallowing, and salivation in patients with ALS, measured in
the aggregate by the CNS-BFS, and by the use of quantitative
measures, such as speech and swallowing rate.
Methods
Study Design and Participants
This phase II, multicenter, double-blind, randomized cross-
over trial was designed to evaluate the effect of DMQ treat-
ment on bulbar functions (speech, swallowing, and salivation)
in patients with ALS.
Sixty patients were recruited from 7 sites chosen by the
Northeast ALS Consortium. Eligible participants were at least
18 years old with a diagnosis of probable or definite ALS as
defined by the revised World Federation of Neurology El
Escorial criteria, disease duration < 2 years from time of diag-
nosis, bulbar dysfunction manifested by dysarthria and/or dys-
phagia as determined by the site principal investigator, guided
by a CNS-BFS score ranging from 50 to 80.
Further requirements included a slow vital capacity of 50%
of normal or greater, intact cognitive function, again deter-
mined by the principal investigator, as well as relatively sound
general health based on a physical examination and baseline
laboratory values obtained at a screening visit. If patients were
taking riluzole, they had to have been on the drug for at least
30 days prior to randomization, and, similarly, patients taking
medication(s) to control salivation had to be on a stable dose
for 30 days prior to be eligible for inclusion in the study.
Exclusion criteria included the following: prior use of
DMQ; current use of dextromethorphan, quinidine, quinine,
mefloquine, opioids, or a known sensitivity to those drugs; a
history of prolonged QT interval, congenital long QT syn-
drome, complete atrioventricular block, or concomitant use
of drugs that both prolong QT interval and are metabolized
by CYP2D6; use of monoamine oxidase inhibitors; invasive
ventilator dependence; use of a feeding tube; treatment with
Botox or radiation for control of sialorrhea within 90 days of
screening in the former instance and 180 days in the latter
instance.
The trial was approved by the institutional review board at
each study site, and informed written consent was obtained
from all patients. A medical monitor was available to resolve
issues that could affect patient care, their eligibility for enroll-
ment in the trial, or continued participation of the patients in
the instance of an adverse event. The study (ClinicalTrials.gov
identifier NCT01806857) was conducted in accordance with
the ethical principles of the Declaration of Helsinki.
Randomization and Masking
Patients meeting the eligibility criteria and accepted into the
study were randomized in a 1:1 ratio to treatment arms that
began with either placebo or DMQ dosing. Study patients, site
investigators, and all other study staff including project and
data management personnel and the study sponsor were
blinded to treatment assignment throughout the study.
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Placebo and DMQ were provided by the sponsor (Avanir
Pharmaceuticals) in identical blister packs and were indistin-
guishable from one another. Both drug and placebo were se-
curely stored under the recommended conditions at a pharma-
cy at the University of Rochester. Research pharmacists who
prepared and shipped drug supplies to each of the clinical
research sites were unblinded as to individual drug assign-
ments in the study.
Procedures
The 2 treatment arms included placebo and DMQ, a drug
known to have a rapid onset of action. Accordingly, each
arm of the trial was designed to be 28 to 30 days in duration,
separated by a 10 to 15-day washout period (see Fig. 1). At the
outset of each treatment period, patients took either a placebo
or DMQ capsule in the evening for 7 days. Subsequently, they
were instructed to take 2 capsules per day at 12-h intervals for
the remainder of the 28-day period. Following the washout
period, patients were switched to the opposite treatment arm,
with an identical dosing regimen. Nuedexta (DMQ) is a com-
bination product containing 20 mg dextromethorphan
hydrobromide and 10 mg quinidine sulfate.
As DMQ is an approved drug with an excellent safety
profile [22], baseline laboratory studies were limited to a com-
plete blood count, standard chemistry panel, and an electro-
cardiogram. The occurrence of adverse events was document-
ed at each study visit, as well as at a final follow-up telephone
call. At the beginning and end of each treatment arm patients
were administered the test battery, outlined in the next section,
to assess their bulbar function.
Outcome Measures
The primary study objective was to determine whether DMQ
exerts a palliative effect on speech, swallowing, and salivation
in patients with ALS, as determined by a significant change in
the CNS-BFS score. The CNS-BFS is a 21-item self-report
scale that assesses 3 domains of bulbar function: speech,
swallowing, and salivation (Table 1). The scale was modeled
on the CNS-LS that has been a robust endpoint in 4 clinical
trials. Initially the CNS-BFS was validated in a large popula-
tion of ALS patients (n = 122) recruited online using a social
networking site [23]. Subsequently, the scale was validated in
120 patients consisting of the 60 participants in the main study
and an additional 60 individuals selected from the general
ALS clinical population recruited from 4 of the 7 participating
ALS research centers.
In the instance of the online study, queries for each of the
21 items that comprise the CNS-BFS were compared with the
patient’s self-reported visual analog scale scores for speech,
swallowing, and salivation. In the subsequent study, the vali-
dation was conducted in a clinic setting, the advantage being
that the patient’s speech, swallowing, and ability to handle
oral secretions were objectively rated as normal or abnormal
by a clinician. For example, in the instance of speech, evalu-
ators determined the character of the patient’s speech based on
3 criteria: loudness, intelligibility, and the presence or absence
of nasality. This assessment was made during a formal timed















Applies most of the
Time
5
Unable to communicate by
speaking
6*
1. My speech is difficult to
understand.
○ ○ ○ ○ ○ ○
*Rating 6 only applies to speech
Bulbar function domains
Salivation Speech Swallowing
1. Excessive saliva is a concern to me.
2. I take medication to control drooling.
3. Saliva causes me to gag or choke.
4. Drooling causes me to be frustrated or
embarrassed.
5. In the morning I notice saliva on my pillow.
6. My mouth needs to be dabbed to prevent
drooling.
7. My secretions are not manageable.
1. My speech is difficult to understand.
2. To be understood I repeat myself.
3. People who understand me tell other people
what I said.
4. To communicate I write things down or use
devices such as a computer.
5. I am talking less because it takes so much
effort to speak.
6. My speech is slower than usual.
7. It is hard for people to hear me.
1. Swallowing is a problem.
2. Cutting my food makes it easier to chew and
swallow.
3. To get food down I have switched to a soft diet.
4. After swallowing I gag or choke.
5. It takes longer to eat.
6. My weight is dropping because I can’t eat
normally.
7. Food gets stuck in my throat.
The patient self-report CNS-BFS interrogates 3 domains of bulbar function: speech, swallowing, and salivation. For each domain, patients are asked to
rate 7 statements or questions on a scale of 1 to 5. Patients unable to speak are assigned a value of 6 for the speech domain questions. Scores can therefore
range from a low of 21 (no symptoms of bulbar dysfunction) to a high of 112
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reading test. This was an objective assessment in that it did not
require any further input from the patients. A similar strategy
was employed to objectively assess the patient’s swallowing
and ability to manage oral secretions.
At baseline, the CNS-BFS total score was well correlated
with the ALS Functional Rating Scale Revised (ALSFRS-R)
bulbar subscale (r = –0.90, p < 0.001). Additionally, the CNS-
BFS speech subscale was highly predictive of clinician assess-
ment of impaired speech [area under the curve (AUC) = 0.95,
p < 0.001]. Similarly, the CNS-BFS swallowing subscale was
well correlated with clinician assessments (choking, spillage,
abnormal effort; AUC = 0.83, p < 0.001), and the CNS-BFS
salivation subscale correlated well with clinician assessments
(resting or stimulated drooling or dabbing; AUC = 0.88, p <
0.001).
Patients were required to complete the self-report CNS-LS
scale to assess the occurrence of emotional lability, also
known as PBA. This was done because it is known that
PBA occurs more commonly in patients with ALSwith bulbar
symptoms [2, 8], and because DMQ is highly effective in
treating PBA. Accordingly, it was of interest to compare the
effect of treatment in both groups, that is, patients with and
without PBA.
Secondary outcome measures included changes in the
self-administered visual analog scales for bulbar function,
the Ashworth spasticity scale, the timed reading of a test
paragraph, the timed swallowing of both solids and liq-
uids, an observed salivation assessment (both resting and
stimulated), and the rater-administered ALSFRS-R. The
latter is an ordinal rating scale used to determine patient’s
capability and independence in 12 functional activities, all
Baseline Visit                                                        Visit 1 Visit 2 Visit 3 Telephone
Call
Screening Period Washout PeriodOn Active Treatment On Active Treatment Washout Period
~90 Screened
30 Subjects on Placebo
30 Subjects on Nuedexta®
30 Subjects on Placebo
30 Subjects on Nuedexta®
21 Days 10-15 Days 28-days (+5 days)28 ±3 Days 28 ±3 Days 
Fig. 1 Study design
Table 2 Study randomization and demographics
Category Patients (n) %
Randomization
Active then placebo 31 51.7









Non-Hispanic or Latino 60 100
Patients taking riluzole 21 35.0
Limb onset 22 36.7
Bulbar onset 38 63.3
Baseline values
Age (y) 57.8 ± 11.1
Age range (y) 26–78
CNS-BFS total score 58.2 ± 13.4
ALSFRS-R total score 34.6 ± 7.0
Mean time symptom onset to trial enrollment (mo) 23.3 ± 21.6
Mean time ALS diagnosis to trial enrollment 9.2 ± 13.3
Data are mean ± SD unless otherwise indicated. CNS-BFS = Center for
Neurologic Study Bulbar Function Scale; ALSFRS-R = Amyotrophic
Lateral Sclerosis Function Rating Scale Revised; ALS = Amyotrophic
Lateral Sclerosis
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of which are relevant in ALS [24]. The ALSFRS-R has
been shown to correlate with changes in strength over
time, closely associates with quality of life measures,
and predicts survival.
Primary safety variables included monitoring adverse
events (AEs), as well as any treatment discontinuations due
to them. Secondary safety variables included vital signs, as
well as concomitant medication requirements. Compliance
was monitored using pill counts in each period.
Statistical Analysis
In a prior study, DMQ was demonstrated to substantially im-
prove PBA [19].
Accordingly, it was assumed that the effect on speech and
swallowing would be of similar magnitude. Based on this, the
crossover treatment design that was modeled on the prior
study predicted an 88% probability that the study would detect
a treatment difference at a 2-sided 0.05 significance level.
The primary efficacy analysis was based on the CNS-BFS
score measured at baseline and at the end of each of the 2
study treatment periods for all patients. The data were ana-
lyzed using an analysis of covariance with terms for baseline
value, treatment group, and period sequence. Patients’ mean
CNS-BFS scores were modeled as a random effect. Estimates
were calculated by least-squared means with SEs. By includ-
ing a period term, the model adjusted for changes in symp-
toms over the course of the study. We tested for a period–
treatment interaction to allow for a carry-over effect. Carry-
Fig. 2 CONSORT diagram.
DMQ = Nuedexta; AE = adverse
event
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over could occur as a result of a curative effect of therapy or an
unblinding of patients on treatment due to efficacy or adverse
treatment effects. This analysis assumes that missing data
were missing at random, conditional on the model and ob-
served data.
The analysis plan for secondary variables was the same as
that for the primary variable. In addition, the percentage of
patients whose speech, swallowing, or salivation was palliated
with treatment was determined by calculating the number of
patients who responded to therapy as a fraction of the total
number of patients treated. Lastly, treatment effects on the 3
domains of bulbar function were assessed.
Results
From April 2013 to November 2014, 90 patients were
screened, 60 of whom were subsequently randomized into
the study. Selected baseline characteristics of patients are
shown in Table 2. A total of 53 patients completed both arms
of the study, one of whom had discontinued study drug during
period 2 (see Fig. 2 for the trial profile). One participant died
during period 1; 2 withdrew consent owing to AEs and 1 in
order to take DMQ open-label; and 3 participants were lost to
follow-up. Upon completion of the trial, each site was visited
by a clinical research administrator who reviewed the case
report forms. Subsequently, all Bqueries^ were resolved and
the electronic database for the study was cross-checked to
assure that it mirrored the data generated at the trial sites. On
10 July 2015 the database was locked and the results of the
study were analyzed following the data analysis format spec-
ified in the trial protocol.
Most patients (93%) were > 90% compliant taking
study drug, based on pill counts (excluding 2 patients
with missing data). The CNS-BFS was, a priori, chosen
as the primary endpoint. An intent-to-treat analysis and
both center and period effects were determined. There
were no center or period effects. For all relevant assess-
ments, comparisons were made between trial periods. For
the primary outcome measure, the mean CNS-BFS for the
placebo arm of the trial was 59.3 (SE 1.10) versus 53.5
(SE 1.07) for the active treatment period (p < 0.001).
Figure 3(A) illustrates the effect on mean CNS-BFS
scores of crossing patients on placebo to the treatment
arm and, conversely, switching patients on DMQ to the
placebo condition. Figure 3(B) shows that almost twice as
many patients had an improvement in their CNS-BFS
scores while on DMQ than when they were on placebo.
The degree of change is also illustrated in the figure.
Each domain of bulbar function in the CNS-BFS
responded positively to DMQ treatment, as follows: 1) saliva-
tion 15.8 versus 14.3 (p = 0.004); 2) speech 24.6 versus 22.2
(p = 0.003); 3) swallowing 18.9 versus 17.1 (p = 0.009).
DMQ treatment also resulted in a significant improvement
in the bulbar component of the more commonly used, rater-
administered ALSFRS-R (p = 0.003). Approximately half of
the patients improved 1 or more points on this measure. The
motor and respiratory components of the ALSFRS-R, howev-
er, were not significantly affected by active treatment.
Treatment positively affected the speech component of the
VAS (p = 0.005), but had no significant effect on the
swallowing or sialorrhea components of this measure (see
Table 3 for a complete summary of primary and secondary
efficacy endpoints).
All of the quantitative measures for speech and
swallowing improved during the DMQ arm of the trial,
although none of these improvements attained a level of
statistical significance. The number of words read per
minute increased from 103 in the placebo period to 107
in the treatment period (p = 0.15). The time it took to
swallow 30 ml of water decreased from 13.1 s in the
placebo group to 12.2 s in the treatment group.
Similarly, the time to swallow a teaspoon of cereal de-
creased with DMQ treatment (19.5 s vs 18.5 s).
As expected, treatment had a robust effect on inappropriate
emotionality as determined by the CNS-LS (13.7 placebo vs
10.7 treated; p < 0.001). At the outset, it was not certain that
DMQ treatment would palliate impaired speech and
swallowing in patients who did not exhibit pseudobulbar af-
fect. However, this was the case, as illustrated in Figure 3(C),
which shows that patients with and without PBA experienced
an equivalent improvement in their total CNS-BFS scores
following DMQ treatment. There was no significant correla-
tion between the baseline CNS-LS score and the response to
treatment (r = –0.054, p = 0.70).
Fig. 3 Effect of Nuedexta (DMQ) versus placebo on changes in the
Center for Neurologic Study Bulbar Function Scale (CNS-BFS; primary
outcome measure). (A) Mean CNS-BFS scores for each treatment arm
(i.e., patients treated with placebo first and then switched to DMQ vs
patients placed on DMQ initially and later switched to placebo) were
calculated during the course of the clinical trial. Measurements were
obtained at baseline, and during 3 subsequent clinical visits. For the group
treated with placebo initially, DMQ treatment was initiated following visit
2 and the drug treatment effect measured at visit 3. For the group treated
with DMQ initially, drug treatment began immediately following the
baseline visit and the effect of treatment was measured at visit 1. The
crossover effect is apparent: CNS-BFS scores declined following the
period of DMQ treatment. (B) Histogram of unadjusted treatment-
dependent change in CNS-BFS total scores among completers.
Negative values indicate larger reductions in CNS-BFS total scores after
receiving DMQ. Positive values indicate larger reductions after receiving
placebo. (C) Interaction plot of CNS-BFS versus pseudobulbar affect
(PBA) status. Improvement in bulbar function (CNS-BFS) associated
with DMQ treatment stratified by presence or absence of PBA at baseline,
defined by a score > 13 on the Center for Neurologic Study Emotional
Lability Scale (CNS-LS). Mean baseline-adjusted CNS-BFS total scores
± 95% confidence intervals (CI) are displayed on the y-axis. DMQ treat-
ment improved bulbar functioning irrespective of whether patients had
PBA
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Patients were monitored for adverse events during both
arms of the study, most of which were mild or moderate
in nature (see Table 4). The most frequent side effects
reported during use of DMQ were constipation, diarrhea,
nausea, and dizziness, similar to results reported in previ-
ous trials evaluating DMQ for the treatment of emotional
lability [5]. AEs reported in > 5% of patients during treat-
ment and placebo intervals of the trial are listed in
Table 5.
Five patients in the trial experienced severe AEs, 2 of
them during the DMQ arm of the trial and 3 patients
during the placebo arm of the trial. One patient died of
respiratory failure secondary to ALS while on the DMQ
arm of the trial. Another patient had to be discontinued
from DMQ therapy because of recurring nausea and diar-
rhea. The number of patients experiencing AEs during
both arms of the trial and the degree to which the AEs
are believed related to study treatment are depicted in
Table 4. There were no clinically relevant changes in vital
signs from baseline through the final visit in the study.
This safety profile is similar to that recently reported in
a multicenter study to assess the safety of DMQ [25].
Discussion
Considering past ALS treatment trials, this study is unique for
several reasons. Firstly, it was driven by reports from patients
and family members who, having been treated for one condi-
tion (PBA), reported unexpected benefit upon seemingly un-
related symptoms. Secondly, the study was conducted over a
relatively short time period (70 days) and, thirdly, a self-report
scale was selected as the principle outcome measure. So far,
most ALS studies have focused on slowing disease
Table 3 Primary and secondary efficacy endpoints






CNS-BFS Total 53.45 59.31 –5.85 1.49 <0.001
CNS-BFS Sialorrhea 14.28 15.81 –1.52 0.51 0.004
CNS-BFS Speech 22.22 24.57 –2.35 0.74 0.003
CNS-BFS Swallowing 17.14 18.92 –1.77 0.65 0.009
VAS Speech 4.97 4.11 0.86 0.30 0.005
VAS Swallowing 7.23 6.93 0.30 0.42 0.47
VAS Sialorrhea 6.78 6.78 –0.01 0.45 0.99
ALSFRS-R Total 34.15 33.70 0.45 0.38 0.25
ALSFRS Bulbar 7.39 6.79 0.60 0.19 0.003
ALSFRS Motor 16.63 16.8 –0.16 0.22 0.46
ALSFRS Respiratory 10.12 10.10 0.02 0.17 0.90
#words read/min 107.12 103.37 3.75 2.54 0.15
Avg swallow water time
(sec)
12.16 13.11 –0.95 0.96 0.33
Avg swallow solids time
(sec)
18.53 19.45 –0.92 1.66 0.58
Ashworth spasticity scale
Score Right Arm
1.65 1.53 0.12 0.09 0.19
Ashworth spasticity scale
Score Left Arm
1.62 1.67 –0.05 0.09 0.58
Ashworth spasticity scale
Score Right Leg
1.94 1.82 0.11 0.07 0.10
Ashworth spasticity scale
Score Left Leg
1.91 1.91 0.00 0.08 0.97
CNS Lability Scale Total 10.79 13.72 –2.92 0.68 <0.001
Mean values in patients’ Center for Neurologic Study Bulbar Function Scale (CNS-BFS) scores (the primary efficacy endpoint) and various secondary
efficacy endpoints are depicted following completion of the placebo and the Nuedexta (DMQ) arms of the trial. Themean differences in patients’ placebo
treatment scores subtracted from their DMQ treatment scores are shown, along with SEs of these mean differences, and p-values of the treatment effect.
Note that statistically significant improvements as a result of DMQ treatment were observed for all 3 components of the primary outcome measure, the
CNS-BFS, as well as the visual analog scale (VAS) speech scale and the bulbar component of the Amyotrophic Lateral Sclerosis Functional Rating Scale
Revised (ALSFRS-R). As expected, DMQ treatment also resulted in improvements in scores measuring inappropriate emotionality [Center for
Neurologic Study Emotional Lability Scale (CNS-LS)]
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progression. This is the first controlled study to report an im-
provement of bulbar function, specifically the enhancement of
speech and swallowing, and improved ability to handle oral
secretions. It had been anticipated that patients’ PBA status
could be a treatment variable. This proved not to be the case.
Patients with and without inappropriate emotionality both
responded to treatment (see Fig. 3C).
While the results of this study are statistically robust, one
could ask whether the result is clinically meaningful. Few
data have been published as to what would constitute a
clinically relevant change in an ALS trial by any measure.
Recently, a group of ALS specialists concluded that a 2-
point change in the ALSFRS-R was Bmoderately or very
clinically meaningful^ in both the gross and bulbar domains
of this scale. Germane to this study, the authors stated that
Bsmaller changes in bulbar and respiratory functional do-
mains were considered more clinically relevant than in other
domains^ [26]. Just under half (49%) of the patients in this
study improved by 1 or more points in the ALSFRS-R bul-
bar domain with DMQ treatment relative to their response
on placebo versus 26% who experienced improvements on
placebo. In short, even by this traditional measure, the re-
sults of the study suggest a favorable clinical outcome. In
this regard, there has been a longstanding concern that ALS
trials, uniformly unsuccessful, might benefit from better as-
sessment tools. Efforts to remedy this, in the instance of
bulbar dysfunction, are ongoing [27–30]. Our data strongly
suggest that the use of patient-generated information may
meet this need. The primary outcome measure in this study,
the CNS-BFS, proved to be superior in all instances to test
instruments historically utilized in clinical trials: visual ana-
log scales, timed measures of speech and swallowing, and
the ALSFRS-R (manuscript in preparation). As observed in
this study, not all self-report measures are equally
Table 4 Adverse event summary by severity and relationship to study drug
DMQ (n = 58) Placebo (n = 57)
Adverse event characteristic # of Events # of Subjects % of Subjects # of Events # of Subjects % of Subjects
Severity
No AEs reported 0 32 55% 0 32 56%
Mild 52 15 26% 32 10 18%
Moderate 17 9 16% 16 12 21%
Severe 2 2 3% 3 3 5%
Relationship to Study Drug
No AEs reported 0 32 55% 0 32 56%
Not related 18 5 9% 30 13 23%
Unlikely related 28 12 21% 14 8 14%
Possibly related 15 6 10% 7 4 7%
Probably related 10 3 5% 0 0 0%
The number and severity of all adverse events (AEs) occurring during placebo and Nuedexta (DMQ) intervals of the trial are listed, along with their
likelihood of being related to study treatment. Counts and percentages of patients summarize the most severe or most closely related event reported for
each patient during a given treatment interval
Table 5 Adverse event summary by MedDRA system organ class, preferred term, and treatment
DMQ (n = 58) Placebo (n = 57)
MedDRA System organ class and Preferred term # of Events # of Subjects % of Subjects # of Events # of Subjects % of Subjects
Gastrointestinal Disorders
Constipation 5 5 9% 2 2 4%
Diarrhea 5 5 9% 1 1 2%
Nausea 5 4 7% 0 0 0%
Nervous System Disorders
Dizziness 10 7 12% 1 1 2%
Adverse events occurring in greater than 5% of subjects during treatment and placebo intervals of the trial are listed. (MedDRA—Medical Dictionary for
Regulatory Activities)
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informative. Whereas all components of the CNS-BFS were
favorably affected with treatment, only the speech visual
analog scale was improved. The reason for this is conjectur-
al. Had this study relied solely on quantitative outcome mea-
sures, such as speech rate or timed swallowing, it would
have failed to detect a significant treatment effect. While a
treatment response might have been evident in a larger
study, it is noteworthy that measures such as speech rate
do not fully reflect all the nuances of speech. In short, a
seemingly objective measure of a function such as speech
may be better assessed by a patient than by an arbitrary
metric. In the future this limitation may be remedied through
the use of computer-assisted assessment of speech.
Recordings obtained from patients in this study are currently
undergoing analysis.
This study leaves some questions unanswered, as it would
have taken a longer study with more patients to do so. The
study was not designed to predict the duration of the treatment
effect or the impact of treatment on disease progression. A
phase III trial to address these considerations is in the planning
stage. Nevertheless, there is anecdotal evidence to suggest a
longstanding benefit of treatment in some patients. But con-
sidering the fact that bulbar onset ALS and bulbar-associated
symptoms are regarded as ominous, portending a grave prog-
nosis, it is reasonable to assume that any treatment that ame-
liorates this aspect of ALS could be a useful addition to the
treatment armamentarium [31, 32].
On reflection, it is tempting to consider whether this trial
offers any clues as to the mode of DMQ’s treatment effect and
any guidance regarding the future design of ALS clinical tri-
als. As previously noted, DMQ exerts pleiotropic pharmaco-
logic effects. Which of its effects, alone or in combination,
account for the favorable treatment outcome in this study will
require further investigation. We doubt that its effect on glu-
tamate is primarily responsible for at least 2 reasons. Firstly,
riluzole has never been reported to enhance bulbar function
but, interestingly patients with bulbar-onset disease were re-
ported to be more responsive to treatment than other patients
[33]. Secondly, ceftriaxone, a drug that upregulates the gluta-
mate transporter, failed to exert any benefits in a large, con-
trolled study [34]. As sigma-1 receptors preferentially deco-
rate brainstem neurons, the most parsimonious explanation for
the effect of DMQ is its ability to facilitate the function of
these motor neurons.
It should be noted that 18 of the 52 patients reported the
same or worse CNS-BFS scores after DMQ treatment relative
to placebo (see Fig. 3B). Nonresponders could represent a
subgroup that is refractory to this mode of treatment for one
reason or another. In the era of personalized medicine, identi-
fication of such a subgroup would be of paramount impor-
tance. A parallel argument could be made that patients’ who
responded to treatment did so based on a nonspecific drug
effect. By analogy with the placebo effect, it might be
assumed that a drug such as DMQ that affected patients’mood
or enhanced arousal, to cite 2 factors, could favorably influ-
ence patients’ perception of their ability to speak and/or swal-
low. While we cannot exclude this possibility, we consider it
unlikely, primarily because treatment had no effect on pa-
tients’ ability to perform a wide range of other activities as
interrogated by the ALSFRS-R. Only the bulbar component
of the ALSFRS-R significantly changed during the treatment
limb of the trial. Patients noted no change in other components
of the ALSFRS-R, including their ability to write, dress, climb
stairs, and so on.
This trial result could conceivably redirect thinking about
future ALS drug trials which, to date, have primarily empha-
sized survival as the primary endpoint. At the minimum, this
trial demonstrates that all motor neurons are not created equal.
It has long been known that cranial nerves innervating the eye
muscles for the most part are resistant to ALS [35]. As we
observed no effect on functions subserved by spinal motor
neurons, it is fair to state that these neurons are qualitatively
different than the cranial motor neurons that facilitate bulbar
functions such as speech and swallowing. Given the success
of this trial, one could argue for placing more emphasis in the
future on treatments that enhance the functional abilities of
patients with ALS and kindred disorders. A step in this direc-
tion might be the recent effort to utilize a skeletal muscle
activator to enhance motor function [36]. Equally important
might be a drug trial to enhance cognitive function in the
instance of ALS associated with frontotemporal dementia.
Until we have a better understanding of ALS, this treatment
strategy may be the fork in the road not yet taken.
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